Why the study?
Does spironolactone use in heart failure patients increase adverse events and reduce treatment compliance compared to non-users and standard therapies?
Does spironolactone use in heart failure patients increase adverse events and reduce treatment compliance compared to non-users and standard therapies?
In a real-world heart failure cohort, spironolactone use was low (15.1%) and associated with higher rates of hyperkalemia and gynecomastia, which likely contributed to significantly lower treatment compliance and persistence compared to other guideline-directed medical therapies.
No takes yet. Share an insight, caveat, or question.
Spironolactone was associated with higher adverse events and lower compliance in real-world HF; leaves open causality and requires randomized confirmation before practice implications.
Lachaîne et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: